- Email: [email protected]
Conclusion
Conclusion
While the lack of available paediatric medicinal products is not the only major important worldwide public health issue, the lack of ‘better medicines for children’ remains an obstacle to ensuring optimal child health globally. Despite the inception of modern psychopharmacology being probably of paediatric nature with Charles Bradley’s 1937 breakthrough observation, a significant gap between adult and paediatric psychopharmacology does exit along with significant unmet needs for pharmacological treatments and prevention strategies of psychiatric disorders in children and adolescents. We are fortunate that Chance, a person with autism, has accepted sharing his story both as a 7-year-old child and now as an adult. Further to making our readers ‘feeling’ the burden of childhood neuropsychiatric and developmental disorders, his contribution is the very reason why we decided to write this book. We need to listen more to the patients’ voices. Paediatric drug development is indeed not just about being compliant with regulatory obligations. It is about making a meaningful change for children worldwide. Triggered by international paediatric regulations and digital innovations, we believe that more research will take place in the field of child and adolescent psychiatry. We are not candid; medical research has a horrible dark history as reflected in the ethical concerns that constitute one storyline of this book. Coming from different backgrounds and experiences but animated by a similar ambition, this book proposes an overview of paediatric development in the field of child and adolescent psychiatry, offering more ‘food for thoughts’ than ‘simple recipes’. Twelve chapters focus on the historical, ethical, scientific, regulatory, and operational aspects of paediatric development trying to maintain a fair balance between updated information and constructive criticism. The path taken is paediatric psychopharmacology, but the concepts are universal. I would like to express my heartfelt thanks to all my co-authors for their great support and dedication, Geneviève Michaux, Beatrice Stirner, Anna I. Parachikova, Jelena Ivkovic, Karel Allegaert, Deborah Lee, and Chance, with a particularly emotional thought to my late friend Klaudius Siegfried, whose generosity, energy, and intellectual curiosity were instrumental in making this book a reality. We modestly hope our contribution will help ‘dreaming’, thinking, innovating, and acting ‘better medicines for children’.
While the lack of available paediatric medicinal products is not the only major important worldwide public health issue, the lack of ‘better medicines for children’ remains an obstacle to ensuring optimal child health globally. Despite the inception of modern psychopharmacology being probably of paediatric nature with Charles Bradley’s 1937 breakthrough observation, a significant gap between adult and paediatric psychopharmacology does exit along with significant unmet needs for pharmacological treatments and prevention strategies of psychiatric disorders in children and adolescents. We are fortunate that Chance, a person with autism, has accepted sharing his story both as a 7-year-old child and now as an adult. Further to making our readers ‘feeling’ the burden of childhood neuropsychiatric and developmental disorders, his contribution is the very reason why we decided to write this book. We need to listen more to the patients’ voices. Paediatric drug development is indeed not just about being compliant with regulatory obligations. It is about making a meaningful change for children worldwide. Triggered by international paediatric regulations and digital innovations, we believe that more research will take place in the field of child and adolescent psychiatry. We are not candid; medical research has a horrible dark history as reflected in the ethical concerns that constitute one storyline of this book. Coming from different backgrounds and experiences but animated by a similar ambition, this book proposes an overview of paediatric development in the field of child and adolescent psychiatry, offering more ‘food for thoughts’ than ‘simple recipes’. Twelve chapters focus on the historical, ethical, scientific, regulatory, and operational aspects of paediatric development trying to maintain a fair balance between updated information and constructive criticism. The path taken is paediatric psychopharmacology, but the concepts are universal. I would like to express my heartfelt thanks to all my co-authors for their great support and dedication, Geneviève Michaux, Beatrice Stirner, Anna I. Parachikova, Jelena Ivkovic, Karel Allegaert, Deborah Lee, and Chance, with a particularly emotional thought to my late friend Klaudius Siegfried, whose generosity, energy, and intellectual curiosity were instrumental in making this book a reality. We modestly hope our contribution will help ‘dreaming’, thinking, innovating, and acting ‘better medicines for children’.